ASCO 2026 preview – GSK gets an early GIST
Strategist-Frontline is set to begin, as the company reports first-line velzatinib data at ASCO.
ASCO 2026 preview – Kelun’s first-line lung cancer win
Optitrop-Lung05 is a hit, as promised, and then some.
ASCO 2026 preview – no GPC3 glory yet for BeOne
First human data for BeOne’s BGB-B2033 lack the wow factor.
ASCO 2026 preview – Pumitamig looks similar to ivonescimab again
First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
ASCO 2026 preview – Black Diamond tries to catch up with Arrivent
Silevertinib efficacy comes close to firmonertinib’s, but toxicity is a new worry.
EHA 2026 preview – Bristol’s celmod reveal
Golcadomide and iberdomide are set to feature at EHA.
Fianlimab flunks its big test
A Libtayo combo fails to beat Keytruda in first-line melanoma.
EHA 2026 preview – a Monumental boost to J&J’s Talvey hopes
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
EHA 2026 preview – BeOne versus Nurix in the front line
Rival BTK degraders face off in CLL patients naive to BTK inhibition.
